Recombinant Human ETF1

• Cat.No.: ETF1-28695TH
• Product Overview: Recombinant fragment of Human eRF1 with N terminal proprietary tag; Predicted MW 36.63 kDa.

Specification

• Description: Termination of protein biosynthesis and release of the nascent polypeptide chain are signaled by the presence of an in-frame stop codon at the aminoacyl site of the ribosome. The process of translation termination is universal and is mediated by protein release factors (RFs) and GTP. A class 1 RF recognizes the stop codon and promotes the hydrolysis of the ester bond linking the polypeptide chain with the peptidyl site tRNA, a reaction catalyzed at the peptidyl transferase center of the ribosome. Class 2 RFs, which are not codon specific and do not recognize codons, stimulate class 1 RF activity and confer GTP dependency upon the process. In prokaryotes, both class 1 RFs, RF1 and RF2, recognize UAA; however, UAG and UGA are decoded specifically by RF1 and RF2, respectively. In eukaryotes, eRF1, or ETF1, the functional counterpart of RF1 and RF2, functions as an omnipotent RF, decoding all 3 stop codons (Frolova et al.
• Protein length: 100 amino acids
• Molecular Weight: 36.630kDa inclusive of tags
• Source: Wheat germ
• Form: Liquid
• Purity: Proprietary Purification
• Storage buffer: pH: 8.00Constituents:0.3% Glutathione, 0.79% Tris HCl
• Storage: Shipped on dry ice. Upon delivery aliquot and store at -80oC. Avoid freeze / thaw cycles.
• Sequences of amino acids: TEEEKILYLTPEQEKDKSHFTDKET GQEHELIESMPLLEWFANNYKKFGA TLEIVTDKSQEGSQFVKGFGGIGGI LRYRVDFQGMEYQGGDDEFFDLDDY
• Sequence Similarities: Belongs to the eukaryotic release factor 1 family.
• Tag: Non

Gene Information

• Gene Name: ETF1 eukaryotic translation termination factor 1 [ Homo sapiens ]
• Official Symbol: ETF1
• Synonyms: ETF1; eukaryotic translation termination factor 1; ERF, ERF1, SUP45L1; eukaryotic peptide chain release factor subunit 1; eRF1; polypeptide chain release factor 1; RF1; sup45 (yeast omnipotent suppressor 45) homolog like 1; TB3 1
• Gene ID: 2107
• mRNA Refseq: NM_004730
• Protein Refseq: NP_004721
• MIM: 600285
• Uniprot ID: P62495
• Chromosome Location: 5q31.2
• Pathway: Eukaryotic Translation Termination, organism-specific biosystem; Gene Expression, organism-specific biosystem; Metabolism, organism-specific biosystem; Metabolism of RNA, organism-specific biosystem; Metabolism of mRNA, organism-specific biosystem
• Function: RNA binding; protein binding; ribosome binding; translation release factor activity; translation release factor activity, codon specific

Reviews

11/25/2022

What sets this protein apart is the outstanding technical support provided by the manufacturer.

09/20/2022

Its versatility allows me to explore its diverse roles in various biochemical and biological processes accurately.

07/18/2019

The ETF1 Protein is of exceptional quality and is precisely tailored to meet my experimental requirements.

Q&As

Are there any ongoing clinical trials related to ETF1 protein disorders?

There may be clinical trials evaluating potential treatments or interventions for ETF1 protein disorders, and individuals and families affected by these disorders can consider participating in such trials.

What are the symptoms of metabolic disorders caused by ETF1 protein dysfunction?

Symptoms may include muscle weakness, lethargy, hypoglycemia, metabolic acidosis, and in some cases, developmental delays and neurological symptoms.

Can ETF1 protein disorders be detected before birth?

Yes, prenatal testing through genetic screening can detect mutations in the ETF1 gene, allowing for early intervention and management.

How are ETF1 protein disorders diagnosed?

Diagnosis typically involves biochemical testing, genetic testing, and metabolic screening to identify abnormalities in fatty acid metabolism.

Can ETF1 protein disorders affect individuals of all ages?

Yes, ETF1 protein disorders can affect individuals of all ages, from newborns to adults, and may present with different symptoms at different stages of life.